Earlier this week, COMPASS Pathways announced that it has acquired an IP portfolio that seeks to cover a “variety of psychedelic and empathogenic substances, some of which are prodrugs.” The company says that the IP was developed with Matthias Grill PhD, via his company MiHKAL (presumably meaning Molecules I Have Known and Loved, in a nod to Shulgin’s seminal publications), which is based in Basel…
